News Conference News ACC 2024 Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6 Yael L. Maxwell April 08, 2024
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017